Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

In development
Reference number: GID-TA11519
Expected publication date: TBC

Documents

Documents created during the development process.

Invitation to participate

Final scope (PDF 166 KB)

Published:

04 April 2025
Final stakeholder list (PDF 98 KB)

Published:

04 April 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6425

Draft matrix post referral (PDF 99 KB)

Published:

06 February 2025
Draft scope post referral (PDF 137 KB)

Published:

06 February 2025